Gapping up
In reaction to strong earnings/guidance: NVRO +35%, RNF +12.9%, RTK +9.3%, VGGL +9.3%, W +8.8%, KBIO +8%, CGA +7.7%, NES +5.2%, DF +5.2%, MBLY +2.8%, GORO +2.7%, TICC +2.7%, ACT +2.6%, ENDP +2.6%, ENDP +2.6%, GWPH +1.8%, BDSI +1.4%, AU +1.2%, KNDI +1.1%, SSYS +0.5%
M&A news: ROSE +32.8% (to be acquired by Noble Energy (NBL) in an all-stock transaction valued at $2.1 billion, or an implied value of $26.62/share), CBK +2.4% (Christopher & Banks considering sale of the company, according to NY Post), SYT +0.9% (Monsanto (MON) considering raising bid for SYT, according to Reuters; also upgraded to Buy from Neutral at UBS)
Select metals/mining stocks trading higher: SSRI +11.1%, RIO +2.6%, VALE +2.2%, GOLD +0.9%, BHP +0.9%
Other news: CALI +38.8% (China stocks strong overnight after PBOC rate cut), ZU +20.9% (Alibaba (BABA) disclosed Friday night in a Form 4 filing that it purchased 11.5 mln shares of ZU), CANF +15.1% (announces it recently received clearance from the EMA to commence dosing patients in Europe in its global Phase II trial for CF102 in the treatment of hepatocellular carcinoma),MYOS +12.7% (announces the initiation of a dose response clinical study of Fortetropin), RXII +6.3% (announces new data for self-delivering RNAi compounds), SFUN +4.3% (China stocks strong overnight after PBOC rate cut), GIGM +3.8% (announces that CFO Dirk Chen has resigned for personal reasons; also reported earnings), TOUR +2.6% (appoints COO Alex Yan as President), ENDP +2.5% (acquires a portfolio of branded and generic injectable products focused on pain, anti-infectives and cardiovascular applications from Aspen Holdings for $130 mln)
Analyst comments: ADRO +4.9% (initiated with a Outperform at Leerink Partners; initiated with a Buy at BofA/Merrill), Z +3.6% (upgraded to Buy from Neutral at Sun Trust Rbsn Humphrey), GDDY +2.8% (initiated with a Overweight at JP Morgan, among others), CDTX +2.1% (initiated with a Outperform at Wedbush), WWWW +1.8% (upgraded to Buy from Hold at Deutsche Bank ),MNST +1.6% (upgraded to Buy from Neutral at Citigroup), SFM +1.2% (upgraded to Outperform from Market Perform at BMO Capital), CSCO +1.2% (upgraded to Outperform from Sector Perform at Pacific Crest), CAT +0.8% (upgraded to Outperform from Neutral at Robert W. Baird), JOY +0.8% (upgraded to Outperform from Neutral at Robert W. Baird), SBH +0.8% (upgraded to Outperform from Mkt Perform at Raymond James), NOK +0.7% (upgraded to Outperform from Neutral at Exane BNP Paribas)
In reaction to strong earnings/guidance: NVRO +35%, RNF +12.9%, RTK +9.3%, VGGL +9.3%, W +8.8%, KBIO +8%, CGA +7.7%, NES +5.2%, DF +5.2%, MBLY +2.8%, GORO +2.7%, TICC +2.7%, ACT +2.6%, ENDP +2.6%, ENDP +2.6%, GWPH +1.8%, BDSI +1.4%, AU +1.2%, KNDI +1.1%, SSYS +0.5%
M&A news: ROSE +32.8% (to be acquired by Noble Energy (NBL) in an all-stock transaction valued at $2.1 billion, or an implied value of $26.62/share), CBK +2.4% (Christopher & Banks considering sale of the company, according to NY Post), SYT +0.9% (Monsanto (MON) considering raising bid for SYT, according to Reuters; also upgraded to Buy from Neutral at UBS)
Select metals/mining stocks trading higher: SSRI +11.1%, RIO +2.6%, VALE +2.2%, GOLD +0.9%, BHP +0.9%
Other news: CALI +38.8% (China stocks strong overnight after PBOC rate cut), ZU +20.9% (Alibaba (BABA) disclosed Friday night in a Form 4 filing that it purchased 11.5 mln shares of ZU), CANF +15.1% (announces it recently received clearance from the EMA to commence dosing patients in Europe in its global Phase II trial for CF102 in the treatment of hepatocellular carcinoma),MYOS +12.7% (announces the initiation of a dose response clinical study of Fortetropin), RXII +6.3% (announces new data for self-delivering RNAi compounds), SFUN +4.3% (China stocks strong overnight after PBOC rate cut), GIGM +3.8% (announces that CFO Dirk Chen has resigned for personal reasons; also reported earnings), TOUR +2.6% (appoints COO Alex Yan as President), ENDP +2.5% (acquires a portfolio of branded and generic injectable products focused on pain, anti-infectives and cardiovascular applications from Aspen Holdings for $130 mln)
Analyst comments: ADRO +4.9% (initiated with a Outperform at Leerink Partners; initiated with a Buy at BofA/Merrill), Z +3.6% (upgraded to Buy from Neutral at Sun Trust Rbsn Humphrey), GDDY +2.8% (initiated with a Overweight at JP Morgan, among others), CDTX +2.1% (initiated with a Outperform at Wedbush), WWWW +1.8% (upgraded to Buy from Hold at Deutsche Bank ),MNST +1.6% (upgraded to Buy from Neutral at Citigroup), SFM +1.2% (upgraded to Outperform from Market Perform at BMO Capital), CSCO +1.2% (upgraded to Outperform from Sector Perform at Pacific Crest), CAT +0.8% (upgraded to Outperform from Neutral at Robert W. Baird), JOY +0.8% (upgraded to Outperform from Neutral at Robert W. Baird), SBH +0.8% (upgraded to Outperform from Mkt Perform at Raymond James), NOK +0.7% (upgraded to Outperform from Neutral at Exane BNP Paribas)